Pfizer Ventures — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Normunity is a cancer immunotherapy company applying an immunology-based approach to identify novel anti-cancer targets at the interface of the immune system and cancer, using proprietary platforms and human cells and tissues.
AI & Machine LearningBiotechHealthtech
Rachel Humphrey(Founding Chief Executive Officer)Lieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)William LaRochelle(Chief Scientific Officer)Stacy M. Plum(Chief Technology Officer)
Co-investorsSanofi VenturesTaiho Ventures, LLCSamsara BioCapitalCanaan PartnersConnecticut InnovationsPfizer Venture Investments+3 more
Cartography develops antibody-based cancer therapies using single-cell sequencing and computational biology to identify precise cellular targets.
AI & Machine LearningBiotechDeep TechMedical DevicesSouth San Francisco, US
Max Mumbach(Founding Scientist, Target Discovery)Jeffrey Verboon(Founding Scientist, Computational Biology)Ansu Satpathy(Founder)Kevin Parker(Chief Executive Officer)Kevin Parker, PhD(Chief Executive Officer, Board Director; co-founder)Ansuman Satpathy, MD, PhD(Co-founder; Board Director)
Co-investors8VCAndreessen HorowitzArtis VenturesGlobal BioAccess FundHAWKTAILPfizer Venture Investments+6 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.